BMS-707035 structure
|
Common Name | BMS-707035 | ||
---|---|---|---|---|
CAS Number | 729607-74-3 | Molecular Weight | 410.420 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C17H19FN4O5S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of BMS-707035BMS-707035 is an HIV-1 integrase (IN) inhibitor with an IC50 value of 15 nM. IC50 Value: 15 nMTarget: HIV IntegraseBMS-707035 was scheduled to be evaluated in a Phase II study to assess the antiretroviral activity, safety, pharmacodynamics, and pharmacokinetics in 50 HIV-infected subjects using a 10-day randomized, double-blind, placebo-controlled, ascending multiple-dose study design. |
Name | 2-(1,1-dioxothiazinan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide |
---|---|
Synonym | More Synonyms |
Description | BMS-707035 is an HIV-1 integrase (IN) inhibitor with an IC50 value of 15 nM. IC50 Value: 15 nMTarget: HIV IntegraseBMS-707035 was scheduled to be evaluated in a Phase II study to assess the antiretroviral activity, safety, pharmacodynamics, and pharmacokinetics in 50 HIV-infected subjects using a 10-day randomized, double-blind, placebo-controlled, ascending multiple-dose study design. |
---|---|
Related Catalog | |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C17H19FN4O5S |
Molecular Weight | 410.420 |
Exact Mass | 410.106018 |
PSA | 133.47000 |
LogP | -2.04 |
Index of Refraction | 1.670 |
Storage condition | -20℃ |
4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)- |
HIV Integrase Inhibitor |
S1366_Selleck |
UNII-7PR4P7YOKT |
2-(1,1-Dioxido-1,2-thiazinan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide |
BMS-707035 |